Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Leo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Oncotarget
|
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Lancet (London, England)
|
November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
Jeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Advances
|
June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
Jeremy S Abramson, William Townsend, Christopher P Fox, et al.
Histopathology
|
March 21, 2013
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups
Teresa Marafioti, Christiane Copie-Bergman, Maria Calaminici, et al.
Leukemia & Lymphoma
|
February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma
Emmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Blood Advances
|
March 27, 2026
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma
Andrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
British Journal of Haematology
|
April 29, 2022
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience
Andrea Kuhnl, Claire Roddie, Amy A Kirkwood, et al.
Blood Advances
|
August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study
Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Hemasphere
|
February 26, 2026
Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK
Andrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Leo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Oncotarget
|
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Lancet (London, England)
|
November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
Jeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Advances
|
June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
Jeremy S Abramson, William Townsend, Christopher P Fox, et al.
Histopathology
|
March 21, 2013
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups
Teresa Marafioti, Christiane Copie-Bergman, Maria Calaminici, et al.
Leukemia & Lymphoma
|
February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma
Emmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Blood Advances
|
March 27, 2026
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma
Andrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
British Journal of Haematology
|
April 29, 2022
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience
Andrea Kuhnl, Claire Roddie, Amy A Kirkwood, et al.
Blood Advances
|
August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study
Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Hemasphere
|
February 26, 2026
Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK
Andrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
Page
of 6